Used in a controlled psychotherapy setting, psychedelics have the potential to treat psychiatric treatments that do not respond to conventional medications, researchers argue.
Study demonstrates the safety and feasibility of psilocybin for the treatment of mental health disorders.
Numerous studies have linked controlled psychedelics to improvements in mental health conditions such as depression and PTSD. In March, the FDA approved Esketamine as a treatment for depression. However, with much stigma surrounding psychedelics, researchers question how many patients would take psychedelic medications if prescribed to them. According to a new study, 40% of people with no experience of psychedelics would be unlikely to take the prescription due to fears of 'brain damage' or a 'bad trip'.
A new study reports two doses of the psychedelic compound psilocybin reduced heavy alcohol consumption by 83% when combined with therapy for those with alcohol use disorder.
While many people report microdosing is beneficial to their mental wellbeing, researchers say more research needs to be conducted to evaluate the psychological and health implications of taking low-dose psychedelics.
Study discussed the benefits of using psychedelics as an antidepressant option for those with depression.
Backing up previous research, a new study reveals psychedelics can have beneficial effects for treating PTSD when combined with traditional trauma-focused psychotherapy. Findings suggest MDMA assisted therapy is significantly more effective at treating patients with persistent PTSD than psychotherapy alone.
Ayahuasca, a psychedelic drink made from Amazonian plants, may help relieve symptoms in those with treatment resistant depression, researchers report.
A new study in Neuroscience of Consciousness adds weight to previous findings about the potential benefits psychedelics could have for treating mental health disorders.
A new study reports psilocybin influences the amygdala, weakening the processing of negative stimuli. Researchers hope the finding could pave the way for new treatment approaches for some psychiatric disorders.
Researchers observe a sustained increase in neural signal diversity in people under the influence of psychedelics.
A new study adds to growing evidence supporting the benefits of psychedelics to treat mental illnesses. Researchers report psilocybin, the psychoactive compound in magic mushrooms, is effective in reducing symptoms for people with treatment resistant depression. The study reveals the compound resets the activity of a brain network associated with depression, helping to improve symptoms in patients for up to 5 weeks following treatment.
